Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07779538 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started2026-09-01
View on ClinicalTrials.gov ↗
This trial is a randomized, open-label, positive-controlled, multicenter phase Ib/III clinical trial, divided into two phases. Phase Ib aims to evaluate the safety and tolerability of SHR-A1811 in combination with bevacizumab as first-line maintenance therapy in participants with epithelial ovarian cancer without pathological progression (PD) after first-line platinum-based doublet chemotherapy plus bevacizumab (hereinafter referred to as "platinum-based triple therapy"). Phase III aims to evaluate the efficacy and safety of SHR-A1811 in combination with bevacizumab versus bevacizumab as maintenance therapy in participants with epithelial ovarian cancer without PD after first-line platinum-based triple therapy.
Trial Details
NCT Number NCT07779538
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Ovarian Cancer
Enrollment 420 participants
Start Date 2026-09-01
Primary Completion 2030-02-28 (estimated)
Study Completion 2030-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-21